Cancer Drug Discovery and Development

Innovations for Next-Generation Antibody-Drug Conjugates

Editors: Damelin, Marc (Ed.)

  • Focus on next-generation ADCs for oncology and other diseases  
  • Description & analysis of current technological innovations for ADCs
  • ADC clinical development in the context of immuno-oncology
see more benefits

Buy this book

eBook 118,99 €
price for Spain (gross)
  • Due: June 14, 2018
  • ISBN 978-3-319-78154-9
  • Digitally watermarked, DRM-free
  • Included format:
  • ebooks can be used on all reading devices
Hardcover 145,59 €
price for Spain (gross)
  • Due: June 14, 2018
  • ISBN 978-3-319-78153-2
  • Free shipping for individuals worldwide
  • The final prices may differ from the prices shown due to specifics of VAT rules
About this book

Antibody-drug conjugates (ADCs) stand at the verge of a transformation.  Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges.  This volume focuses on the next generation of ADCs and the innovations that will enable them.  The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies.  While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases.

The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties.  However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing.  The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies.  These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.

About the authors

Marc Damelin is Senior Director, Biology at Mersana Therapeutics in Cambridge, Massachusetts. His group is responsible for the discovery of therapeutic ADCs enabled by Mersana's proprietary linker-payload-scaffold technologies. Prior, Marc spent 10 years at Pfizer Inc. in the Oncology Research Unit, where he led ADC discovery teams and ultimately oversaw the ADC portfolio. He received his Ph.D. in Biophysics from Harvard University and conducted postdoctoral research at Columbia University Medical School as a Fellow of the Damon Runyon Cancer Research Foundation. 

Buy this book

eBook 118,99 €
price for Spain (gross)
  • Due: June 14, 2018
  • ISBN 978-3-319-78154-9
  • Digitally watermarked, DRM-free
  • Included format:
  • ebooks can be used on all reading devices
Hardcover 145,59 €
price for Spain (gross)
  • Due: June 14, 2018
  • ISBN 978-3-319-78153-2
  • Free shipping for individuals worldwide
  • The final prices may differ from the prices shown due to specifics of VAT rules
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Innovations for Next-Generation Antibody-Drug Conjugates
Editors
  • Marc Damelin
Series Title
Cancer Drug Discovery and Development
Copyright
2018
Publisher
Humana Press
Copyright Holder
Springer International Publishing AG, part of Springer Nature
eBook ISBN
978-3-319-78154-9
DOI
10.1007/978-3-319-78154-9
Hardcover ISBN
978-3-319-78153-2
Series ISSN
2196-9906
Edition Number
1
Number of Pages
X, 381
Topics